Psychedelics: promising but controversial

• The research is promising but incomplete.
• Reimbursement remains uncertain.
• Workforce readiness may be the largest scaling challenge.

Note: The term “psychedelics” is too broad for clinical purposes because these compounds are not interchangeable, differing significantly in mechanism, subjective experience and safety profile. However, we will collapse all the categories for this article since we are not dealing with the clinical aspects.³

Psychedelics occupy a unique legal position because many remain Schedule I controlled substances under federal law. 

The executive order contemplates ways to accelerate federal review and potentially facilitate rescheduling. However, until such changes occur, companies operating within the psychedelic ecosystem must navigate complex regulatory frameworks involving the FDA, DEA, state regulators, health care providers and research institutions. 

The current evidence base features promising results in some areas while remaining controversial and incomplete in others.⁴

Several psychedelic compounds, including psilocybin-based therapies and MDMA-assisted treatments, have produced encouraging clinical trial results for conditions such as depression, post-traumatic stress disorder (PTSD), addiction and other difficult-to-treat mental health disorders. 

The FDA has granted Breakthrough Therapy designation to multiple psychedelic drug programs, reflecting preliminary evidence that they may offer significant advantages over existing treatments.^{5, 6}  

At the same time, the FDA declined to approve MDMA-assisted therapy for PTSD in 2024, despite positive Phase 3 trial outcomes. This illustrates that regulators historically require rigorous proof of safety and effectiveness.⁷  

The executive order aims to encourage faster consideration of qualifying psychedelic products. However, even if one or more psychedelic therapies gain approval, health care organizations would still face practical requirements that may ultimately prove more challenging than obtaining regulatory approval itself.⁸  

The biggest constraint on psychedelic medicine adoption is likely to be health care delivery infrastructure rather than clinical science.

Traditional psychiatric medications are often prescribed through brief physician visits and taken at home. Many psychedelic treatment models, by contrast, involve extensive preparation sessions, supervised dosing sessions and follow-up integration or therapy sessions. 

Some psychedelic treatment models require 6-8 hours of supervised clinical monitoring, creating substantially higher labor demands than traditional psychiatric prescribing.⁹ 

For healthcare systems, the question becomes whether sufficient infrastructure exists to deliver treatment at scale.¹⁰ For employers and insurers, the question is whether the outcomes justify the associated costs and resource requirements.

If psychedelic therapies become more widely available, workforce development could become a major bottleneck.

The healthcare system currently faces shortages in several behavioral health professions. Psychedelic-assisted treatment models often require specialized training beyond traditional psychiatric or psychological education.¹¹  

Therefore, successful commercialization may depend less on manufacturing the drug and more on building the workforce capable of administering it appropriately. This resembles the challenges seen during the rollout of other specialized treatments where provider capacity — not product availability — became the limiting factor. For example, here we discuss the complexities in treating patients with the current crop of Alzheimer’s disease drugs.

Another practical issue involves payment.

Many promising health care innovations have struggled not because they lacked clinical value but because insurers were unwilling to reimburse for them. Psychedelic therapies may face a similar challenge.

The direct drug cost could represent only a portion of the overall expense. Similar to Alzheimer’s, much of the cost may come from clinician time, facility use, monitoring and supporting services. 

Payers will likely require evidence that these treatments produce durable improvements that offset health care costs elsewhere, such as hospitalization, disability, substance-use treatment or lost productivity.¹²   

For business leaders, reimbursement may ultimately determine market adoption more than scientific enthusiasm. Even highly effective therapies face barriers when economic models are unclear.

Finally, the success of psychedelic medicines will depend heavily on social acceptance.

Decades of legal restrictions and cultural stigma have created strong associations between psychedelics and recreational drug use. Even if therapies receive regulatory approval, organizations will need to address concerns among patients, providers, employers, policymakers and the public.¹⁵  

That said, legal and political support has broadened and interest now spans a wider range of states and political viewpoints. Nevertheless, public confidence must still be earned through transparent evidence, consistent regulation and demonstrated patient outcomes.¹⁶

The administration's executive order does not establish psychedelic medicines as proven therapies, nor does it guarantee regulatory approval. What it does accomplish is elevating the field to a level of national visibility that few emerging healthcare sectors ever achieve.¹⁷  

The most important business implication of psychedelic medicines may be that reimbursement, workforce capacity and treatment infrastructure may determine adoption more than FDA approval alone.

Optum Rx continuously monitors the pharmaceutical development pipeline to assess emerging therapies, evaluate clinical evidence and anticipate the operational, financial and patient-care implications of newly approved treatments. 

Once a drug receives FDA approval, Optum Rx conducts a rigorous review of its safety, efficacy, appropriate use and value relative to existing standards of care to inform formulary placement, utilization management strategies and coverage recommendations.